{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:11:58Z","timestamp":1771974718541,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T00:00:00Z","timestamp":1653782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Ministry of Science and Higher Education of the Russian Federation","award":["075-15-2021-1086 (15.\u0418\u041f.21.0015)"],"award-info":[{"award-number":["075-15-2021-1086 (15.\u0418\u041f.21.0015)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Immune evasion of SARS-CoV-2 undermines current strategies tocounteract the pandemic, with the efficacy of therapeutic virus-neutralizing monoclonal antibodies (nAbs) being affected the most. In this work, we asked whether two previously identified human cross-neutralizing nAbs, iB14 (class VH1-58) and iB20 (class VH3-53\/66), are capable of neutralizing the recently emerged Omicron (BA.1) variant. Both nAbs were found to bind the Omicron RBD with a nanomolar affinity, yet they displayed contrasting functional features. When tested against Omicron, the neutralizing activity of iB14 was reduced 50-fold, whereas iB20 displayed a surprising increase in activity. Thus, iB20 is a unique representative of the VH3-53\/66-class of nAbs in terms of breadth of neutralization, which establishes it as a candidate for COVID-19 therapy and prophylactics.<\/jats:p>","DOI":"10.3390\/jpm12060895","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:50:51Z","timestamp":1653814251000},"page":"895","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["VH3-53\/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages"],"prefix":"10.3390","volume":"12","author":[{"given":"Sergey V.","family":"Kulemzin","sequence":"first","affiliation":[{"name":"Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Sergeeva","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, 197376 St. Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4029-6518","authenticated-orcid":false,"given":"Konstantin O.","family":"Baranov","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2830-4236","authenticated-orcid":false,"given":"Andrey A.","family":"Gorchakov","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey V.","family":"Guselnikov","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-4078","authenticated-orcid":false,"given":"Tatyana N.","family":"Belovezhets","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga Yu.","family":"Volkova","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Najakshin","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai A.","family":"Chikaev","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-0836","authenticated-orcid":false,"given":"Daria M.","family":"Danilenko","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, 197376 St. Petersburg, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-4238","authenticated-orcid":false,"given":"Alexander V.","family":"Taranin","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, Siberian Branch of Russian Academy of Sciences, 630090 Novosibirsk, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/bioinformatics\/btaa739","article-title":"CoV-AbDab: The coronavirus antibody database","volume":"37","author":"Raybould","year":"2021","journal-title":"Bioinformatics"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMc2100362","article-title":"New SARS-CoV-2 Variants\u2014Clinical, Public Health, and Vaccine Implications","volume":"384","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody evasion by the P.1 strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41421-021-00340-8","article-title":"Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern","volume":"7","author":"Gorchakov","year":"2021","journal-title":"Cell Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.immuni.2021.08.013","article-title":"A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants","volume":"54","author":"Schmitz","year":"2021","journal-title":"Immunity"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/science.abh1766","article-title":"Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants","volume":"373","author":"Wang","year":"2021","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","article-title":"Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation","volume":"53","author":"Seydoux","year":"2020","journal-title":"Immunity"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e02492\u2013e20","DOI":"10.1128\/mBio.02492-20","article-title":"Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera","volume":"12","author":"Oguntuyo","year":"2021","journal-title":"mBio"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Boonyaratanakornkit, J., Sholukh, A.M., Gray, M., Bossard, E.L., Ford, E.S., Corbett, K.S., Corey, L., and Taylor, J.J. (2021). Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43. Viruses, 13.","DOI":"10.3390\/v13102075"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eabn8543","DOI":"10.1126\/scitranslmed.abn8543","article-title":"SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies","volume":"5","author":"Lusvarghi","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","first-page":"022","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"3","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"108274","DOI":"10.1016\/j.celrep.2020.108274","article-title":"An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain","volume":"33","author":"Wu","year":"2020","journal-title":"Cell Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1126\/science.abm5835","article-title":"SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies","volume":"375","author":"Reincke","year":"2022","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gruell, H., Vanshylla, K., Korenkov, M., Tober-Lau, P., Zehner, M., M\u00fcnn, F., Janicki, H., Augustin, M., Schommers, P., and Sander, L.E. (2022). Delineating antibody escape from Omicron variants. bioRxiv.","DOI":"10.1101\/2022.04.06.487257"},{"key":"ref_26","first-page":"5","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Rep. Med."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/6\/895\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:47Z","timestamp":1760138447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/6\/895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,29]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jpm12060895"],"URL":"https:\/\/doi.org\/10.3390\/jpm12060895","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,29]]}}}